Current and Novel Therapies for Cluster Headache: A Narrative Review

Area of Science:

• Neurology
• Headache Medicine

Background:

• Cluster headache (CH) is a debilitating primary headache disorder with up to 1.3% prevalence, often misdiagnosed and increasingly diagnosed in women.
• Characterized by severe unilateral pain and autonomic symptoms, CH significantly affects patient well-being and productivity.
• Genetic and lifestyle factors contribute to CH, with pathophysiology involving the central and peripheral nervous systems, including the hypothalamus and CGRP.

Purpose of the Study:

• To review the current understanding of cluster headache (CH) epidemiology, pathophysiology, and treatment options.
• To highlight the limitations of existing therapies and the need for improved management strategies.
• To explore emerging treatments and future research directions for CH.

Main Methods:

• Literature review of epidemiological data, genetic associations, and pathophysiological mechanisms of CH.
• Analysis of current pharmacological (acute and preventive) and nonpharmacological treatment modalities.
• Evaluation of interventional procedures and novel therapeutic approaches, including neuromodulation and potential psychedelic roles.

Main Results:

• CH diagnosis is increasing, particularly in women, with onset typically around age 30.
• Established treatments include oxygen, sumatriptan for acute attacks, and verapamil, lithium, or CGRP monoclonal antibodies for prevention.
• Interventional options like nerve stimulation and emerging therapies show promise but require careful safety consideration.

Conclusions:

• Despite available treatments, patients with CH face significant burdens due to limited efficacy and side effects.
• Multifaceted treatment strategies integrating lifestyle modifications, pharmacological, and interventional approaches are essential.
• Future research focusing on novel targets, procedures, and psychedelics is crucial for improving CH patient outcomes.